story of the week
Dupilumab for Patients With COPD With Type 2 Inflammation Indicated by Eosinophil Counts
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The New England Journal of Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts
N. Engl. J. Med 2023 Jul 20;389(3)205-214, SP Bhatt, KF Rabe, NA Hanania, CF Vogelmeier, J Cole, M Bafadhel, SA Christenson, A Papi, D Singh, E Laws, LP Mannent, N Patel, HW Staudinger, GD Yancopoulos, ER Mortensen, B Akinlade, J Maloney, X Lu, D Bauer, A Bansal, LB Robinson, RM AbdulaiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.